03.06.24|Sophie ShulmanThe partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders.
13.09.20|CTechYou reap what you sow: The pharmaceutical giant is partnering up with researchers to try and find the next Copaxone
23.08.20|CTechMicrofluidic chips that simulate human tissue enable us to conduct medical experiments in ways that could not have been even imagined only a few years ago. Two leading Israeli researchers report from the turbulent Israeli front line of the global 'organ-on-a-chip' sector
24.12.19|Hagar Ravet NanoGhosts turns stem cells into a drug delivery system that specifically targets cancerous tumors
04.03.19|Adi PickMechoulam is a professor at the Institute for Drug Research at the Hebrew University of Jerusalem and is the subject of a 2015 movie documentary called The Scientist
03.01.19|Lilach BaumerIn December, Teva reached a confidential settlement and licensing agreement with drug manufacturer Neos Therapeutics, regarding its generic version for Neos' ADHD drug
09.12.18|Lilach BaumerNovartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
04.12.18|CTechRedHill’s new pill managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving the standard of care
29.11.18|Lilach BaumerCalled Truxima, the drug has been approved to treat several conditions of non-Hodgkin’s lymphoma
05.07.18|CTechViAqua develops a particle-based matrix for delivering antiviral medication to shrimp
31.05.18|Dror ReichThe Nasdaq-listed, Israeli based company received the FDA’s approval to expand the use of flagship burn treatment NexoBrid to those suffering from Sulfur Mustard injuries
27.04.18|Tofi StolerTo carry out the plan, Kanabo is partnering with San Francisco-Based Cannabis Extract Manufacturer Constance Therapeutics
09.04.18|Lilach BaumerTherapix Biosciences announced the successful completion of phase 2 clinical trial of its cannabinoid-based drug, conducted at Yale University Monday
17.12.17|Uri Tal-TenneThe cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
31.10.17|Lilach BaumerMapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
18.10.17|Dror Reich and Lilach BaumerTeva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year